National Institute on Aging; Notice of Closed Meeting, 11363-11364 [2017-03446]
Download as PDF
Federal Register / Vol. 82, No. 34 / Wednesday, February 22, 2017 / Notices
therapy, or as needing alternative
treatment strategies.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will
be royalty bearing, and the prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published notice, the National
Cancer Institute receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR part 404.
Complete applications for a license in
the prospective field of use that are filed
in response to this notice will be treated
as objections to the grant of the
contemplated Exclusive Patent License
Agreement. Comments and objections
submitted to this notice will not be
made available for public inspection
and, to the extent permitted by law, will
not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: February 15, 2017.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2017–03402 Filed 2–21–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Meeting
sradovich on DSK3GMQ082PROD with NOTICES
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
National Cancer Institute Board of
Scientific Advisors.
The meeting will be open to the
public, with attendance limited to space
available. Individuals who plan to
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting. The meeting
will also be videocast and can be
accessed from the NIH Videocasting and
Podcasting Web site (https://
videocast.nih.gov/).
Name of Committee: National Cancer
Institute Board of Scientific Advisors.
Date: March 21, 2017.
Time: 8:30 a.m. to 5:00 p.m.
Agenda: Acting Director’s Report: Ongoing
and New Business; RFA and RFP Concept
Reviews; and Scientific Presentations.
Place: National Institutes of Health, 31
Center Drive, Building 31, C-Wing, 6th Floor,
Room 10, Bethesda, MD 20892.
VerDate Sep<11>2014
16:05 Feb 21, 2017
Jkt 241001
Contact Person: Paulette S. Gray, Ph.D.,
Director, Division of Extramural Activities,
National Cancer Institute—Shady Grove,
National Institutes of Health, 9609 Medical
Center Drive, 7th Floor, Rm. 7W444,
Bethesda, MD 20892, 240–276–6340, grayp@
mail.nih.gov.
Name of Committee: National Cancer
Institute Board of Scientific Advisors.
Date: March 22, 2017.
Time: 8:30 a.m. to 12:00 p.m.
Agenda: Acting Director’s Report: Ongoing
and New Business; RFA and RFP Concept
Reviews; and Scientific Presentations.
Place: National Institutes of Health, 31
Center Drive, Building 31, C-Wing, 6th Floor,
Room 10, Bethesda, MD 20892.
Contact Person: Paulette S. Gray, Ph.D.,
Director, Division of Extramural Activities,
National Cancer Institute—Shady Grove,
National Institutes of Health, 9609 Medical
Center Drive, 7th Floor, Rm. 7W444,
Bethesda, MD 20892, 240–276–6340, grayp@
mail.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
Information is also available on the
Institute’s/Center’s home page: https://
deainfo.nci.nih.gov/advisory/bsa/bsa.htm,
where an agenda and any additional
information for the meeting will be posted
when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: February 15, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–03387 Filed 2–21–17; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
11363
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the National Cancer
Institute Clinical Trials and Translation
Research Advisory Committee, March 8,
2017, 8:00 a.m. to March 8, 2017, 3:00
p.m., National Institutes of Health,
Building 31, C-Wing, 6th Floor, Rooms
9 and 10, 31 Center Drive, Bethesda, MD
20892 which was published in the
Federal Register on January 11, 2017, 81
FR 3342.
This meeting notice is amended to
change the meeting format and start and
end times. The meeting will now be
held virtually from 11:00 a.m. to 1:30
p.m. due to a change in the agenda
which reduced the time required for
deliberation and discussion. The
meeting will still be held at the National
Institutes of Health, Building 31, CWing, 6th Floor, Rooms 9 and 10, 31
Center Drive, Bethesda, MD 20892 and
can also be accessed via NIH Videocast
at https://videocast.nih.gov. This
meeting is open to the public.
Dated: February 16, 2017.
Melanie J. Gray-Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–03448 Filed 2–21–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Aging Special Emphasis Panel; Second Stage
P01 Review.
Date: March 15, 2017.
Frm 00028
Fmt 4703
Sfmt 4703
E:\FR\FM\22FEN1.SGM
22FEN1
11364
Federal Register / Vol. 82, No. 34 / Wednesday, February 22, 2017 / Notices
Time: 10:30 a.m. to 11:45 a.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Gateway Building, Suite 2W200, 7201
Wisconsin Avenue, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Ramesh Vemuri, Ph.D.,
Chief, Scientific Review Branch, Scientific
Review Branch, National Institute on Aging,
National Institutes of Health, 7201 Wisconsin
Avenue, Suite 2C–212, Bethesda, MD 20892,
301–402–7700, rv23r@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
Dated: February 16, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–03446 Filed 2–21–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Licensing information and copies of the
patent applications listed below may be
obtained by communicating with the
indicated licensing contact at the
Technology Transfer and Intellectual
Property Office, National Institute of
Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852; tel.
301–496–2644. A signed Confidential
Disclosure Agreement will be required
to receive copies of unpublished patent
applications.
SUPPLEMENTARY INFORMATION:
Technology descriptions follow.
Inhibition of host heme oxygenase-1
as an adjunctive treatment to improve
the outcome of conventional antibiotic
chemotherapy of Mycobacterium
tuberculosis (Mtb) infection.
sradovich on DSK3GMQ082PROD with NOTICES
SUMMARY:
Description of Technology
This invention describes the
adjunctive use of heme oxygenase-1
VerDate Sep<11>2014
16:05 Feb 21, 2017
Jkt 241001
(HO–1) inhibitors to improve the
outcome of conventional antibiotic
treatment for tuberculosis. The existent
standard of care requires prolonged
administration of drug. Due to the long
duration of treatment, methods that can
more rapidly control tuberculosis in
patients are clearly needed.
NIAID researchers have discovered
that inhibition of host HO–1 reduces
Mycobacterium tuberculosis (Mtb)
growth in vivo and, more importantly,
when used as an adjunct to
conventional chemotherapy, results in a
marked improvement in pulmonary
bacterial control. In particular, it was
found using a mouse model that HO–1
inhibitors enhance bacterial clearance
when used in conjunction with
conventional antibiotic therapy.
Further, no obvious toxic side effects
were found. Since this host-directed
strategy does not directly target the
pathogen itself, it may have an added
advantage as a treatment for infections
with antibiotic-resistant Mtb strains.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404, as well as for further
development and evaluation under a
research collaboration.
Potential Commercial Applications:
• Therapeutic for Mtb.
Competitive Advantages:
• Innovative, more rapidly effective
therapeutics for tuberculosis are sorely
needed due to the continued importance
of TB as a global infectious disease and
the increasing emergence of multi-drug
resistant strains.
• This invention is a host-directed
therapy.
Development Stage: Pre-Clinical.
Inventors:
F. Alan Sher, NIAID, NIH
Diego L. Costa, NIAID, NIH
Bruno B. Andrade, NIAID, NIH
Publications: Costa, Diego L., et al.
‘‘Pharmacological Inhibition of Host
Heme Oxygenase-1 Suppresses
Mycobacterium tuberculosis Infection In
Vivo by a Mechanism Dependent on T
Lymphocytes.’’ mBio 7.5 (2016):
e01675–16.
Intellectual Property: HHS Reference
No. E–174–2016/0—U.S. Patent
Application No. 62/357,558, filed 07/
01/2016.
Licensing Contact: James M.
Robinson; James.Robinson4@nih.gov;
301–761–7542.
Collaborative Research Opportunity:
The National Institute of Allergy and
Infectious Diseases is seeking statements
of capability or interest from parties
interested in collaborative research to
further evaluate HO–1 inhibitors in
PO 00000
Frm 00029
Fmt 4703
Sfmt 4703
treating human tuberculosis. For
collaboration opportunities, please
contact James M. Robinson;
James.Robinson4@nih.gov; 301–761–
7542.
Dated: February 16, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2017–03451 Filed 2–21–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel;
Radiotherapy in Combination with Systemic
Agents.
Date: March 20, 2017.
Time: 12:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W234, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Adriana Stoica, Ph.D.,
Scientific Review Officer, Resources and
Training Review Branch, Division of
Extramural Activities, National Cancer
Institute, NIH, 9609 Medical Center Drive,
Room 7W234, Bethesda, MD 20892–9750,
240–276–6368, Stoicaa2@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; NCI
Provocative Questions 12.
Date: March 23, 2017.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W030, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Jennifer C. Schiltz, Ph.D.,
Scientific Review Officer, Special Review
Branch, Division of Extramural Activities,
E:\FR\FM\22FEN1.SGM
22FEN1
Agencies
[Federal Register Volume 82, Number 34 (Wednesday, February 22, 2017)]
[Notices]
[Pages 11363-11364]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-03446]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Aging Special Emphasis
Panel; Second Stage P01 Review.
Date: March 15, 2017.
[[Page 11364]]
Time: 10:30 a.m. to 11:45 a.m.
Agenda: To review and evaluate grant applications.
Place: National Institute on Aging, Gateway Building, Suite
2W200, 7201 Wisconsin Avenue, Bethesda, MD 20892, (Telephone
Conference Call).
Contact Person: Ramesh Vemuri, Ph.D., Chief, Scientific Review
Branch, Scientific Review Branch, National Institute on Aging,
National Institutes of Health, 7201 Wisconsin Avenue, Suite 2C-212,
Bethesda, MD 20892, 301-402-7700, rv23r@nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging
Research, National Institutes of Health, HHS)
Dated: February 16, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-03446 Filed 2-21-17; 8:45 am]
BILLING CODE 4140-01-P